Literature DB >> 18300946

Functional characterization of human xanthine oxidase allelic variants.

Mutsumi Kudo1, Toshiko Moteki, Takamitsu Sasaki, Yumiko Konno, Shuta Ujiie, Akemi Onose, Michinao Mizugaki, Masaaki Ishikawa, Masahiro Hiratsuka.   

Abstract

OBJECTIVE: Xanthine oxidase (XO) catalyzes the oxidation of endogenous and exogenous purines and pyrimidines. In this study, we speculated that individual variations in XO activity are caused by genetic variations in the XO gene.
METHODS: To investigate the genetic variations in XO in 96 Japanese participants, denaturing high-performance liquid chromatography was used. To assess the effects of these variations on enzymatic activity, wild-type XO and 21 types of variant XO--including those in the database and those just discovered--were transiently expressed in COS-7 cells.
RESULTS: Three nonsynonymous single nucleotide polymorphisms, including 514G>A (Gly172Arg), 3326A>C (Asp1109Thr), and 3662A>G (His1221Arg) were identified in Japanese participants. Functional characterization of 21 XO variants showed a deficiency in enzyme activity in two variants (Arg149Cys and Thr910Lys); low activity (intrinsic clearance, CLint: 22-69% compared with the wild-type) in six variants (Pro555Ser, Arg607Gln, Thr623Ile, Asn909Lys, Pro1150Arg, and Cys1318Tyr); and high activity (CLint: approximately two-fold higher than that in the wild-type) in two variants (Ile703Val and His1221Arg).
CONCLUSION: These results suggest that several single nucleotide polymorphisms in the XO gene are involved in individual variations in XO activity. In addition, such findings will be useful to identify xanthinuria patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300946     DOI: 10.1097/FPC.0b013e3282f55e2e

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  20 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

2.  Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.

Authors:  Katerina Wroblova; Michal Kolorz; Marian Batovsky; Vladimir Zboril; Jana Suchankova; Milan Bartos; Boris Ulicny; Igor Pav; Ladislava Bartosova
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

3.  Distribution of xanthine oxidase activity in a Nigerian population.

Authors:  Ayorinde Adehin; Oluseye Oladotun Bolaji
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

Review 4.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

5.  A case of xanthinuria type I with a novel mutation in xanthine dehydrogenase.

Authors:  Akira Iguchi; Takaaki Sato; Mihoko Yamazaki; Kazuyuki Tasaki; Yasushi Suzuki; Noriaki Iino; Hiroshi Hasegawa; Kimiyoshi Ichida; Ichiei Narita
Journal:  CEN Case Rep       Date:  2016-03-03

Review 6.  Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.

Authors:  Lisa K Stamp; Tony R Merriman; Murray L Barclay; Jasvinder A Singh; Rebecca L Roberts; Daniel F B Wright; Nicola Dalbeth
Journal:  Semin Arthritis Rheum       Date:  2014-05-09       Impact factor: 5.532

Review 7.  Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.

Authors:  Shivani Deswal; Anshu Srivastava
Journal:  J Clin Exp Hepatol       Date:  2017-02-06

8.  Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.

Authors:  Matthew B Carroll; Derek M Smith; Thomas L Shaak
Journal:  Rheumatol Int       Date:  2016-10-31       Impact factor: 2.631

9.  Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Authors:  Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

Review 10.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.